Skip to main content

Table 5 Odds ratio estimates (and confidence intervals) for risk of death due to any cause by day 28 associated with the significant factors included into the final logistic regression model, each adjusted for both of the other factors

From: Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial

Patient characteristic

Odds ratio for 28-day ACM (95% CI)

Baseline bacteremia with any pathogen (vs no bacteremia)*

2.7 (1.1, 7.1)

Concomitant vasopressor use (vs no vasopressor use)

5.4 (2.6, 11.0)

Meropenem treatment (vs ceftolozane/tazobactam treatment)§

2.3 (1.2, 4.5)

  1. ACM, all-cause mortality. CI, confidence interval
  2. *Adjusting for vasopressor use and treatment
  3. Adjusting for bacteremia and treatment
  4. §Adjusting for bacteremia and vasopressor use